Sciencare has built an innovative drug delivery R&D platform centered on long-acting, sustained-release implant technology. We focus on applying our core technology to innovative treatments in areas including addiction, central nervous system (CNS) disorders, oncology, and infectious diseases, resulting in multiple technology platforms.

1. Implant Technology Platform

Exemplified by our naltrexone hydrochloride implant, which has received marketing approval from China's NMPA. This platform utilizes poly(D,L-lactide) to encapsulate the drug into microspheres, compressed into a core tablet. This core is subsequently coated with a rate-controlling membrane using our proprietary encapsulation technology. This multi-stage release technology has been successfully scaled up for commercial manufacturing.

2. Micro-Implant Technology Platform

Utilizing a continuous manufacturing process to produce rod-shaped implants for minimally invasive, subcutaneous injection with a dedicated device. Multiple candidates developed on this platform have completed pharmaceutical development and preclinical evaluation and are now entering the IND application stage.

3. Excipient Synthesis Technology Platform

A proprietary platform for pharmaceutical-grade biodegradable polymers (PDLLA, PLLA, PLGA). It integrates R&D, pilot-scale, and commercial manufacturing capabilities within a GMP-compliant Grade C cleanroom, with an annual production capacity of up to 1,000 kg.

Sciencare welcomes collaboration and technical exchange with pharmaceutical industry peers to advance formulation science and create mutual value.

Contact: Dr. Qu, quwei@sciencare.cn